U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Showing 1 - 10 of 11 results

Status:
Investigational

Class (Stereo):
CHEMICAL (ACHIRAL)



Scopoletin is a coumarin that can be isolated from plants of the genus Scopolia. It has been identified as a natural antifungal compound. Scopoletin was also demonstrated to be an MAO inhibitor capable of increasing dopamine levels in mice and is the...
Status:
US Previously Marketed
First approved in 1959

Class (Stereo):
CHEMICAL (ACHIRAL)


Conditions:

Nialamide is a non-selective, irreversible monoamine oxidase inhibitor of the hydrazine class. It was previously used as an antidepressant (trade name Niamid) but was withdrawn by Pfizer in 1963 due to the risk of hepatotoxicity.
Status:
US Previously Marketed
First approved in 1955

Class (Stereo):
CHEMICAL (ACHIRAL)



Iproniazid is a non-selective, irreversible monoamine oxidase inhibitor (MAO) of the hydrazine class. It was originally developed for the treatment of Tuberculosis, but in 1952, its antidepressant properties were discovered when researchers noted tha...
Status:
Possibly Marketed Outside US

Class (Stereo):
CHEMICAL (ACHIRAL)



Amezinium is a sympathomimetic used for its vasopressor effects in the treatment of hypotensive states. Amezinium inhibited monoamine oxidase (MAO) activity. Amezinium antagonized the response to tyramine and blocked neuronal uptake of noradrenaline....
Status:
Possibly Marketed Outside US

Class (Stereo):
CHEMICAL (ACHIRAL)


Caroxazone, 2-oxo-2H-1,3-benzoxazine-3(4H)-acetamide, was a psychotropic agent which in clinical studies was shown to possess a relevant antidepressant activity and was used to treat depression. This drug acts as a reversible inhibitor on both monoam...
Status:
Possibly Marketed Outside US

Class (Stereo):
CHEMICAL (ACHIRAL)



Budipine is an antiparkinsonian drug, which was developed by Byk Gulden (now Takeda) for the treatment of Parkinson's disease. The drug has multiple mechanisms of action: it was found to interfere with dopamine biosynthesis, mainly by inhibiting MAO-...
Status:
US Previously Marketed
First approved in 1955

Class (Stereo):
CHEMICAL (ACHIRAL)



Iproniazid is a non-selective, irreversible monoamine oxidase inhibitor (MAO) of the hydrazine class. It was originally developed for the treatment of Tuberculosis, but in 1952, its antidepressant properties were discovered when researchers noted tha...
Status:
Possibly Marketed Outside US

Class (Stereo):
CHEMICAL (ACHIRAL)



Amezinium is a sympathomimetic used for its vasopressor effects in the treatment of hypotensive states. Amezinium inhibited monoamine oxidase (MAO) activity. Amezinium antagonized the response to tyramine and blocked neuronal uptake of noradrenaline....

Showing 1 - 10 of 11 results